2026-01-27 - Analysis Report
**Company Overview:**
Eli Lilly and Company is a global pharmaceutical firm focused on developing and commercializing innovative medicines that improve patient outcomes and reduce costs.

**Comparison of Return Rate:**
| Ticker | Cumulative Return |
| --- | --- |
| LLY (Review Stock) | 660.89% |
| VOO (Comparison Stock, S&P 500) | 127.58% |
| Divergence (max: 577.90, min: -22.40, current: 535.60) | 535.60 |
| Relative Divergence (e.g., for 100% fluctuations: 90 means the top 90%) | 93.00% |

The review stock LLY has significantly outperformed the S&P 500 (VOO) with a cumulative return of 660.89% compared to 127.58% for VOO, indicating a divergence of 535.60.

**Alpha, Beta Analysis:**
| Period | CAGR | MDD | Alpha | Beta | Capital (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 46.0% | 14.2% | 38.0% | 0.7 | 103.7B |
| 2017-2019 | 54.0% | 12.1% | 29.0% | 0.7 | 117.8B |
| 2018-2020 | 82.0% | 19.7% | 58.0% | 0.7 | 151.4B |
| 2019-2021 | 128.0% | 19.7% | 64.0% | 0.7 | 247.6B |
| 2020-2022 | 169.0% | 19.7% | 165.0% | 0.7 | 328.0B |
| 2021-2023 | 259.0% | 18.2% | 241.0% | 0.5 | 522.6B |
| 2022-2024 | 349.0% | 23.9% | 320.0% | 0.6 | 692.1B |
| 2023-2025 | 454.0% | 33.4% | 378.0% | 0.7 | 963.4B |

LLY has demonstrated stable growth with rising alpha and beta values across different periods, reflecting increasing market influence and returns.

**Recent Stock Price Fluctuations:**
|  | Value |
| --- | --- |
| Close | $1,062.75 |
| Last-Market | {'price': 1062.75, 'previousClose': 1064.29, 'change': -0.14} |
| 5-day SMA | $1,066.85 |
| 20-day SMA | $1,069.54 |
| 60-day SMA | $1,029.54 |

The stock has declined with a small -0.14% change. The short-term moving averages (5-day and 20-day SMA) are above the current price, and the long-term moving average (60-day SMA) is below, indicating possible price recovery but with potential uncertainty.

**RSI, PPO Indicators, and Risk Level:**
* Market Risk Indicator (MRI) = 0.70 (~Medium Investment Recommended)
* RSI = 54.15
* PPO = -0.28
* Hybrid Signal: Buy (Cash 0%); Recent (20 days) relative divergence change = 3.90 (+); improving

The stock shows a moderate RSI of 54.15, slightly above the 50%, and a negative PPO, reflecting downward momentum. The stock's risk profile is deemed medium investment recommended.

**Recent News & Significant Events:**
1. "[2026-01-23] Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance (news.google.com)"
2. "[2026-01-26] FDA Delays Lillyâ€™s Weight-Loss Pill: Is the Stock Still a Buy for 2026? - NAI500 (news.google.com)"
3. "[2026-01-16] Buy The Dip In LLY Stock? - Forbes (news.google.com)"
4. "[2026-01-26] Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? - The Motley Fool (news.google.com)"
5. "[2026-01-21] Eli Lilly: Buy Ahead Of Its Earnings Day (Preview) (NYSE:LLY) - Seeking Alpha (news.google.com)"
6. "[2026-01-26] Eli Lilly and Company $LLY Shares Sold by OneAscent Financial Services LLC - MarketBeat (news.google.com)"

These news headlines suggest potential regulatory challenges, market uncertainty, and stock performance fluctuation but generally recommend investing in LLY.

**Analyst Opinions:**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.70 (~Buy)
- Opinions: 28
- Target Price (avg/high/low): 1112.68 / 1500.00 / 770.00

Analysts have a buy consensus with a mean rating of 1.70 and a target price average of $1,112.68.

**Recent Earnings Analysis:**
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-30 | 6.22 | $17.60B |
| 2025-08-07 | 6.3 | $15.56B |
| 2025-05-01 | 3.07 | $12.73B |
| 2024-10-30 | 1.08 | $11.44B |
| 2025-10-30 | 1.08 | $11.44B |

LLY's revenue has steadily increased with a notable increase in 2025, with corresponding changes in earnings per share (EPS). Overall, LLY's financial performance suggests solid growth across the review period.

**Financial Information (5.1 & 5.2):**
Revenue and Profitability:
| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $17.60B | 82.91% |
| 2025-06-30 | $15.56B | 84.27% |
| 2025-03-31 | $12.73B | 82.53% |
| 2024-12-31 | $13.53B | 82.24% |
| 2024-09-30 | $11.44B | 81.02% |

Capital and Profitability:
| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $23.79B | 23.46% |
| 2025-06-30 | $18.27B | 30.98% |
| 2025-03-31 | $15.76B | 17.50% |
| 2024-12-31 | $14.19B | 31.07% |
| 2024-09-30 | $14.24B | 6.81% |

The financial data highlights a strong growth in revenue, consistently high profit margins, rising equity, and varying return on equity (ROE) across the quarters, showing overall financial stability and growth.

**Comprehensive Analysis (Summary):**

LLY has demonstrated significant outperformance compared to the S&P 500 (VOO) with a cumulative return of 660.89% and a divergence of 535.60 from VOO's 127.58%. It has shown consistent growth, increasing alpha, and beta across multiple periods.

Considering recent fluctuations, LLY has a moderate RSI and a negative PPO but remains a buy signal with a target price average of $1,112.68. Stock price analysis reveals a short-term decline but potential recovery due to long-term moving averages.

News headlines hint at possible regulatory challenges but recommend investing in LLY. Analysts hold a strong buy consensus, further supporting LLY's investment potential. Recent earnings analysis highlights a steadily increasing revenue with improved financial performance across the review period.

Overall, LLY appears to be an attractive investment opportunity with a strong historical performance and promising financial outlook.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.